Publications

Filters (1)
January 31, 2024

Debio 0123, a selective, brain penetrant WEE1 inhibitor in clinical development for patients with solid tumors

Read more
November 17, 2023

A Phase 1/2 study of the WEE1 inhibitor Debio 0123 in combination with temozolomide +/– radiotherapy in adults with recurrent…

Read more
June 3, 2023

Debio 0123-101, a phase 1 trial of Debio 0123 in combination with carboplatin in advanced solid tumors: safety, pharmacokinetic, and…

Read more
April 19, 2023

Debio 0123 is a selective WEE1 inhibitor that effectively penetrates the brain and demonstrates anti-tumor activity in preclinical models of…

Read more
January 25, 2023

Debio 0123, A Selective WEE1 Inhibitor in Clinical Development for Patients with Solid Tumors

Read more
September 10, 2022

Pharmacodynamic marker modulation of the selective WEE1 inhibitor Debio 0123 in patient biopsies from phase 1 clinical trial

Read more
April 12, 2022

The WEE1 inhibitor Debio 0123 enhances the efficacy of standard of care DNA damaging agents in lung cancer models

Read more
September 17, 2020

First-in-Human phase 1 study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced…

Read more
April 2, 2019

Antitumor activity of the novel oral highly selective Wee1 inhibitor Debio 0123

Read more